There were 639 press releases posted in the last 24 hours and 437,936 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Theravance Biopharma Completes Enrollment in All Three Phase 3 Clinical Studies of Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image